GGrantIndex
← Leaderboards

Myriam Marianne Chaumeil

University Of California, San Francisco

$7,418,051
Attributed
$14,128,231
Total exposure
9
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $5.1M · FY201624
$10M$7.5M$5M$2.5M$0
'16
'17
'18
'19
'20
'21
'22
'23
'24

Funding mix

By agency

NIH$14,128,231 · 9

By mechanism

R01$5,516,586 · 3
RF1$3,597,332 · 1
R33$2,624,637 · 1
R21$1,323,979 · 3
R61$1,065,697 · 1

Most similar at University Of California, San Francisco

Same institution · by research overlap

Others in their field

Top investigators on “Alzheimer&Apos

Research focus

Alzheimer&AposImaging ModalityEvaluationMagnetic Resonance ImagingImageBrainIn VivoMetabolicLesionMonitorImaging ApproachDetectionRegimenValidationBiological MarkersLeadPre-Clinical ModelPathway InteractionsCognitiveInnovationMetabolic ImagingPyruvateImaging StudyResponse

Grant awards (25)

Theranostic Metabolic Imaging of Oxidative Stress in Multiple Sclerosis.$201,875
R21 · FY2024 · AI · contact PI
Development and validation of novel models for cerebral small vessel disease and vascular cognitive impairment$783,698
R33 · FY2023 · NS
Imaging cerebral metabolic impairment in AD using Deuterium MRI$719,216
R01 · FY2023 · AG · contact PI
Application of Hyperpolarized 13C Magnetic Resonance Imaging to Detect Target Inhibition of NF-kB Activation and Response in Primary CNS Lymphoma$571,523
R01 · FY2023 · CA
Theranostic Metabolic Imaging of Oxidative Stress in Multiple Sclerosis.$242,250
R21 · FY2023 · AI · contact PI
Development and validation of novel models for cerebral small vessel disease and vascular cognitive impairment$155,505
R33 · FY2023 · NS
Diversity Supplement-Massoudi$106,768
R33 · FY2023 · NS
Development and validation of novel models for cerebral small vessel disease and vascular cognitive impairment$782,056
R33 · FY2022 · NS
Application of Hyperpolarized 13C Magnetic Resonance Imaging to Detect Target Inhibition of NF-kB Activation and Response in Primary CNS Lymphoma$584,054
R01 · FY2022 · CA
Development and validation of novel models for cerebral small vessel disease and vascular cognitive impairment$796,610
R33 · FY2021 · NS
Application of Hyperpolarized 13C Magnetic Resonance Imaging to Detect Target Inhibition of NF-kB Activation and Response in Primary CNS Lymphoma$613,413
R01 · FY2021 · CA
MR metabolic Imaging of Multiple Sclerosis$346,719
R01 · FY2021 · NS · contact PI
Imaging innate and adaptive immune response in MS using using [18F]F-AraG PET and hyperpolarized 13C MRSI$161,500
R21 · FY2021 · AI · contact PI
Application of Hyperpolarized 13C Magnetic Resonance Imaging to Detect Target Inhibition of NF-kB Activation and Response in Primary CNS Lymphoma$644,765
R01 · FY2020 · CA
Development and validation of novel models for cerebral small vessel disease and vascular cognitive impairment$560,704
R61 · FY2020 · NS
MR metabolic Imaging of Multiple Sclerosis$346,719
R01 · FY2020 · NS · contact PI
Imaging innate and adaptive immune response in MS using using [18F]F-AraG PET and hyperpolarized 13C MRSI$282,479
R21 · FY2020 · AI · contact PI
Understand and probing disrupted glucose metabolism in Alzheimer's disease$3,597,332
RF1 · FY2019 · AG
Application of Hyperpolarized 13C Magnetic Resonance Imaging to Detect Target Inhibition of NF-kB Activation and Response in Primary CNS Lymphoma$650,020
R01 · FY2019 · CA
Development and validation of novel models for cerebral small vessel disease and vascular cognitive impairment$504,993
R61 · FY2019 · NS
MR metabolic Imaging of Multiple Sclerosis$346,719
R01 · FY2019 · NS · contact PI
MR metabolic Imaging of Multiple Sclerosis$346,719
R01 · FY2018 · NS · contact PI
MR metabolic Imaging of Multiple Sclerosis$346,719
R01 · FY2017 · NS · contact PI
In vivo metabolic imaging of neuroinflammation after TBI$198,125
R21 · FY2017 · NS
In vivo metabolic imaging of neuroinflammation after TBI$237,750
R21 · FY2016 · NS